Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Spirapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 15/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spirapril SCHEMBL11052621 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7340600 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7338593 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL7338589 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL1649585 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL6506406 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL11052614 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL3785516 | 1.00 | ABCB11 (0.98) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL387353 | 0.99 | ABCB11 (1.00) | ABCB11ACELMNASMN1; SMN2PDE3A | |
| Spirapril SCHEMBL14660503 | 0.99 | ABCB11 (1.00) | ABCB11ACELMNASMN1; SMN2PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10868 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4611904-A1 | COMPOSITIONS AND METHODS FOR TREATING NF1 AND OTHER CONDITIONS | Liby, Karen (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250241896-A1 | L-PAG DERIVATIVES FOR TREATMENT OF SLEEP DISORDERED BREATHING (SDB) | THE UNIVERSITY OF CHICAGO (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12280038-B2 | L-pag derivatives for treatment of sleep disordered breathing (SDB) | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-1990002117-A1 | MERCAPTO-ACYLAMINO ACID ANTIHYPERTENSIVES | SCHERING CORPORATION (US) | 1990-03-08 | — | — | WO | claimed |
| EP-0355784-A1 | Mercapto-acylamino acid antihypertensives | SCHERING CORPORATION (US) | 1990-02-28 | — | — | EP | claimed |
| EP-0336950-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| EP-0320097-A1 | Controlled absorption diltiazem formulations | ELAN CORPORATION, Plc (IE) | 1989-06-14 | — | — | EP | claimed |
| WO-1989003691-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-05-05 | — | — | WO | claimed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | claimed |
| EP-0050800-B1 | CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-06-18 | — | — | EP | claimed |
| US-4470972-A | 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids | SCHERING CORPORATION (US) | 1984-09-11 | — | — | US | claimed |
| EP-0052991-A1 | Carboxyalkyl amino acid derivatives of various substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-02 | — | — | EP | claimed |
| EP-0050800-A1 | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1982-05-05 | — | — | EP | claimed |